DFDavid Neal Franz

David Neal Franz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


David Neal Franz has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Cindy Tudor

    2 shared publications
  • Darcy A. Krueger

    Department of Pediatrics and Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA

    2 shared publications
  • Karen Agricola

    From the Departments of Pediatrics and Neurology (D.A.K., K.A., C.T., M.M., D.N.F.) and the Departments of Pediatrics and Radiology (M.M.C.), Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    2 shared publications
  • Marguerite M. Care

    From the Departments of Pediatrics and Neurology (D.A.K., K.A., C.T., M.M., D.N.F.) and the Departments of Pediatrics and Radiology (M.M.C.), Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    2 shared publications
  • Tarek Sahmoud

    2 shared publications
  • Anna Byars

    1 shared publication

Latest Publications

  • Nursing Implications for the Lifelong Management of Tuberous Sclerosis Complex

    by Karen Agricola, Cindy Tudor, Darcy Krueger, David Neal Franz

    Tuberous sclerosis complex (TSC) is a genetic disorder that can affect multiple organ systems, including the brain, heart, skin, kidney, and lung, by formation of benign hamartomas. It can be associated with autism, epilepsy, and other neurocognitive and behavioral disabilities. The incidence of TSC is approximately 1 in 6,000 live births, but it may be underdiagnosed. Mutations to either the TSC1 (coding for hamartin) or TSC2 (coding for tuberin) genes are present in 85% of patients with TSC. The TSC1/TSC2 protein dimer complex is a crucial inhibitory element in the mammalian target of rapamycin (mTOR) complex 1 pathway that regulates cell growth and proliferation. The manifestations of TSC usually require management over the entire life of the patient. Until recently, there were few options, other than surgical removal, for treating the symptoms of TSC related to growth of hamartomas. Increased understanding of the genetic cause of the disease and the underlying dysregulation of the mTOR pathway has led to clinical trials of mTOR inhibitors including sirolimus and everolimus. This article will review the various manifestations of TSC and describe treatment strategies, recommendations for surveillance, and use of mTOR inhibitors in their management.


  • Top Cited Papers

    Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma

    by Darcy A. Krueger, Marguerite M. Care, Karen Agricola, Cindy Tudor, Maxwell Mays, David Neal Franz

    Objective: To report long-term efficacy and safety data for everolimus for the treatment of subependymal giant cell astrocytoma (SEGA) in patients with tuberous sclerosis complex (TSC). Methods: This was an open-label extension phase of a prospective, phase 1–2 trial (NCT00411619) in patients ≥3 years of age with SEGA associated with TSC. Patients received oral everolimus starting at 3 mg/m2 per day and subsequently titrated, subject to tolerability, to attain whole blood trough concentrations of 5–15 ng/mL. Change in SEGA volume, seizures, and safety assessments were the main outcome measures. Results: Of 28 patients enrolled, 25 were still under treatment at the time of analysis. Median dose was 5.3 mg/m2/day and median treatment duration was 34.2 months (range 4.7–47.1). At all time points (18, 24, 30, and 36 months), primary SEGA volume was reduced by ≥30% from baseline (treatment response) in 65%–79% of patients. All patients reported ≥1 adverse event (AE), mostly grade 1/2 in severity, consistent with that previously reported, and none led to everolimus discontinuation. The most commonly reported drug-related AEs were upper respiratory infections (85.7%), stomatitis (85.7%), sinusitis (46.4%), and otitis media (35.7%). No drug-related grade 4 or 5 events occurred. Conclusion: Everolimus therapy is safe and effective for longer term (median exposure 34.2 months) treatment of patients with TSC with SEGA. Classification of evidence: This study provides Class III evidence that everolimus, titrated to trough serum levels of 5–15 ng/mL, was effective in reducing tumor size in patients with SEGA secondary to TSC for a median of 34 months.


  • Top Cited Papers

    Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial

    by David Neal Franz, Elena Belousova, Steven Sparagana, E Martina Bebin, Michael Frost, Rachel Kuperman, Olaf Witt, Michael H Kohrman, J Robert Flamini, Joyce Y Wu, et al.


  • Top Cited Papers
    Open Access

    Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis

    by Darcy A. Krueger, Marguerite M. Care, Katherine Holland, Karen Agricola, Cynthia Tudor, Prajakta Mangeshkar, Kimberly A. Wilson, Anna Byars, Tarek Sahmoud, David Neal Franz

    Neurosurgical resection is the standard treatment for subependymal giant-cell astrocytomas in patients with the tuberous sclerosis complex. An alternative may be the use of everolimus, which inhibits the mammalian target of rapamycin, a protein regulated by gene products involved in the tuberous sclerosis complex.


  • Current Management of Tuberous Sclerosis Complex

    by Darcy A Krueger, David N. Franz

    Tuberous sclerosis complex (TSC) is an important cause of epilepsy, autism, and renal and pulmonary disease in children and adults. The clinical course of TSC and the prognosis and appropriate therapy for TSC patients are often different than that for individuals with epilepsy, renal tumors, or interstitial lung disease from other causes. This article reviews the current therapeutic recommendations for medical and surgical management of neurologic, renal, and pulmonary manifestations of TSC. In addition, recent clinical trials using inhibitors of the mammalian target of rapamycin (mTOR) have demonstrated regression of astrocytomas, angiofibromas, and angiomyoliomas, as well as improved pulmonary function in persons with TSC.